<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Skin and Venereal Diseases</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Skin and Venereal Diseases</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский журнал кожных и венерических болезней</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1560-9588</issn><issn publication-format="electronic">2412-9097</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">702862</article-id><article-id pub-id-type="doi">10.17816/dv702862</article-id><article-id pub-id-type="edn">OLUICD</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>DERMATOLOGY</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ДЕРМАТОЛОГИЯ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">A modern approach to the differential diagnosis of erythrodermic pityriasis rubra pilaris: a retrospective study at V.A. Rakhmanov Clinic of Skin and Venereal Diseases. Part 1</article-title><trans-title-group xml:lang="ru"><trans-title>Современный подход к дифференциальной диагностике эритродермической формы болезни Девержи: ретроспективное исследование на базе Клиники кожных и венерических болезней им. В.А. Рахманова. Часть 1</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2482-1754</contrib-id><contrib-id contrib-id-type="spin">2500-7989</contrib-id><name-alternatives><name xml:lang="en"><surname>Olisova</surname><given-names>Olga Yu.</given-names></name><name xml:lang="ru"><surname>Олисова</surname><given-names>Ольга Юрьевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Medicine), Professor, Corresponding Member of the Russian Academy of Sciences</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор, чл.-корр. РАН</p></bio><email>olisovaolga@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5800-4800</contrib-id><contrib-id contrib-id-type="spin">8013-3256</contrib-id><name-alternatives><name xml:lang="en"><surname>Teplyuk</surname><given-names>Natalia P.</given-names></name><name xml:lang="ru"><surname>Теплюк</surname><given-names>Наталия Павловна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Medicine), Professor</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор</p></bio><email>teplyukn@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7968-9829</contrib-id><contrib-id contrib-id-type="spin">8028-5545</contrib-id><name-alternatives><name xml:lang="en"><surname>Grekova</surname><given-names>Ekaterina V.</given-names></name><name xml:lang="ru"><surname>Грекова</surname><given-names>Екатерина Владимировна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Medicine), Assistant Professor</p></bio><bio xml:lang="ru"><p>канд. мед. наук, доцент</p></bio><email>grekova_kate@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0002-3750-4635</contrib-id><contrib-id contrib-id-type="spin">3591-6849</contrib-id><name-alternatives><name xml:lang="en"><surname>Gushcha</surname><given-names>Polina I.</given-names></name><name xml:lang="ru"><surname>Гуща</surname><given-names>Полина Игоревна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>polinaguscha276@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0004-0638-6992</contrib-id><contrib-id contrib-id-type="spin">7563-9893</contrib-id><name-alternatives><name xml:lang="en"><surname>Bagdasaryan</surname><given-names>Goarik A.</given-names></name><name xml:lang="ru"><surname>Багдасарян</surname><given-names>Гоарик Артуровна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>goga05022001@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0007-7602-0162</contrib-id><contrib-id contrib-id-type="spin">3300-8218</contrib-id><name-alternatives><name xml:lang="en"><surname>Miagkova</surname><given-names>Anastasiia A.</given-names></name><name xml:lang="ru"><surname>Мягкова</surname><given-names>Анастасия Александровна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>myan_03@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6458-3191</contrib-id><contrib-id contrib-id-type="spin">9713-9534</contrib-id><name-alternatives><name xml:lang="en"><surname>Pankov</surname><given-names>Kirill A.</given-names></name><name xml:lang="ru"><surname>Панков</surname><given-names>Кирилл Александрович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>pankovka15@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">The First Sechenov Moscow State Medical University (Sechenov University)</institution></aff><aff><institution xml:lang="ru">Первый Московский государственный медицинский университет имени И.М. Сеченова (Сеченовский Университет)</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2026-04-06" publication-format="electronic"><day>06</day><month>04</month><year>2026</year></pub-date><pub-date date-type="pub" iso-8601-date="2026-05-17" publication-format="electronic"><day>17</day><month>05</month><year>2026</year></pub-date><volume>29</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>191</fpage><lpage>205</lpage><history><date date-type="received" iso-8601-date="2026-02-16"><day>16</day><month>02</month><year>2026</year></date><date date-type="accepted" iso-8601-date="2026-02-20"><day>20</day><month>02</month><year>2026</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2026, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2026, Эко-Вектор</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">Эко-Вектор</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2029-05-17"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref></license></permissions><self-uri xlink:href="https://rjsvd.com/1560-9588/article/view/702862">https://rjsvd.com/1560-9588/article/view/702862</self-uri><abstract xml:lang="en"><p><bold>BACKGROUND:</bold> Pityriasis rubra pilaris (Devergie disease) is a rare chronic inflammatory skin disease classified as papulosquamous dermatosis. Despite the pathognomonic clinical and pathomorphological signs, diagnosing erythrodermic pityriasis rubra pilaris can be difficult because clinical signs such as diffuse erythema and scaling affecting more than 80% of the body surface area can also be observed in other dermatoses, including psoriasis and cutaneous T-cell lymphoma (mycosis fungoides).</p> <p><bold>AIM:</bold> The work aimed to assess the clinical, anamnestic, histological, and immunohistochemical signs of erythrodermic pityriasis rubra pilaris and perform a differential diagnosis with psoriasis and mycosis fungoides.</p> <p><bold>METHODS:</bold> A retrospective analysis of medical history, clinical manifestations, and laboratory parameters was performed in 147 patients with erythroderma admitted to the V.A. Rakhmanov Clinic of Skin and Venereal Diseases, University Clinical Hospital No. 2, Sechenov University, in 2014–2024. Of these, 17 (11.6%) patients had erythrodermic pityriasis rubra pilaris. For differential diagnosis, the study included 26 (17.7%) patients with mycosis fungoides and 104 (70.7%) patients with psoriatic erythroderma. Skin biopsies were performed, followed by histological, immunohistochemical, and molecular biological tests (as needed).</p> <p><bold>RESULTS:</bold> At admission, the diagnosis of pityriasis rubra pilaris was made based on clinical signs and medical history in 64.7% of patients (<italic>n</italic> = 11), with histological confirmation in 52.9% of cases (<italic>n</italic> = 9). In patients with nonspecific histological signs, repeated skin biopsies from several sites were performed to verify the diagnosis. Immunohistochemical and molecular biological tests were used to rule out mycosis fungoides. The clinical and histological signs of erythroderma can be nonspecific, necessitating a comprehensive diagnostic approach. Therefore, the medical history, clinical manifestations, and laboratory and imaging findings must be considered and compared. Moreover, it is essential to rule out mycosis fungoides, a particularly aggressive disease.</p> <p><bold>CONCLUSION:</bold> The findings highlight the need for differential diagnosis algorithms for disorders associated with erythroderma.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Обоснование.</bold> Болезнь Девержи (красный волосяной лишай) ― редкое хроническое воспалительное заболевание кожи, относящееся к группе папулосквамозных дерматозов. Несмотря на патогномоничные клинические и патоморфологические признаки, нередко диагностика эритродермической формы болезни Девержи становится затруднительной, поскольку клиническая картина в виде диффузной эритемы и шелушения более чем 80% кожного покрова может наблюдаться и при других дерматозах, например, при псориазе и Т-клеточной лимфоме кожи (грибовидном микозе).</p> <p><bold>Цель исследования</bold> ― оценить клинико-анамнестические, гистологические и иммуногистохимические признаки эритродермической формы болезни Девержи и провести дифференциальный диагноз с псориазом и грибовидным микозом.</p> <p><bold>Методы.</bold> Проведён ретроспективный анализ анамнестических данных, клинических проявлений и лабораторных показателей 147 случаев эритродермий среди пациентов, госпитализированных в Клинику кожных и венерических болезней им. В.А. Рахманова УКБ № 2 Сеченовского Университета в 2014–2024 годах, их них 17 (11,6%) пациентов с эритродермической формой болезни Девержи, для дифференциальной диагностики ― 26 (17,7%) пациентов с грибовидным микозом и 104 (70,7%) с псориатической эритродермией. Проведена оценка биопсии кожи с дальнейшим гистологическим, иммуногистохимическим и молекулярно-биологическим исследованием при необходимости.</p> <p><bold>Результаты.</bold> Диагноз болезни Девержи первично при поступлении установлен на основании клинико-анамнестических данных у 64,7% (<italic>n</italic> = 11) пациентов, гистологически подтверждён в 52,9% (<italic>n</italic> = 9) случаев. При неспецифических гистологических признаках для верификации диагноза пациентам проведены неоднократные биопсии кожи из нескольких участков. Для исключения грибовидного микоза осуществляли иммуногистохимические и молекулярно-биологические исследования. Клинические и гистологические признаки эритродермий могут носить неспецифический характер, что подчёркивает важность комплексного подхода к постановке диагноза. Таким образом, следует учитывать и сопоставлять данные анамнеза пациента, клинические проявления заболевания и результаты лабораторно-инструментальной диагностики. Особое внимание стоит обратить на исключение такого агрессивно протекающего заболевания, как грибовидный микоз.</p> <p><bold>Заключение.</bold> На основании полученных результатов исследования актуальной является разработка алгоритма дифференциальной диагностики заболеваний, сопровождающихся развитием эритродермии.</p></trans-abstract><kwd-group xml:lang="en"><kwd>Devergie disease</kwd><kwd>pityriasis rubra pilaris</kwd><kwd>psoriasis</kwd><kwd>mycosis fungoides</kwd><kwd>erythroderma</kwd><kwd>differential diagnosis</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>болезнь Девержи</kwd><kwd>питириаз красный волосяной отрубевидный</kwd><kwd>псориаз</kwd><kwd>грибовидный микоз</kwd><kwd>эритродермия</kwd><kwd>дифференциальная диагностика</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Joshi TP, Duvic M. Pityriasis rubra pilaris: an updated review of clinical presentation, etiopathogenesis, and treatment options. Am J Clin Dermatol. 2024;25(2):243–259. doi: 10.1007/s40257-023-00836-x EDN: MUYKTS</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Olisova OY, Teplyuk NP, Plieva LR, Lomonosov KM. The erythrodermal form of Devergie’s disease. Russian journal of skin and venereal diseases. 2014;17(1):18–20. EDN: RWIOUD</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Finzi AF, Altomare G, Bergamaschini L, Tucci A. Pityriasis rubra pilaris and retinol-binding protein. Br J Dermatol. 1981;104(3):253–256. doi: 10.1111/j.1365-2133.1981.tb00946.x</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Potestio L, D’Agostino M, Portarapillo A, et al. Emerging role of biologic drugs targeting IL-17 and IL-23: pityriasis rubra pilaris. Life. 2024;14(8):923. doi: 10.3390/life14080923 EDN: KCYAMN</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Shao S, Chen J, Swindell WR, et al. Phospholipase A2 enzymes represent a shared pathogenic pathway in psoriasis and pityriasis rubra pilaris. JCI Insight. 2021;6(20):e151911. doi: 10.1172/jci.insight.151911 EDN: XXDIVW</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Liu T, Li S, Ying S, et al. The IL-23/IL-17 pathway in inflammatory skin diseases: from bench to bedside. Front Immunol. 2020;11:594735. doi: 10.3389/fimmu.2020.594735 EDN: UZSICL</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Velasco RC, Shao C, Cutler B, et al. Guselkumab for pityriasis rubra pilaris and dysregulation of IL-23/IL-17 and NFkB signaling. JAMA Dermatol. 2024;160(6):641–645. doi: 10.1001/jamadermatol.2024.0257 EDN: FJGACB</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Moos S, Mohebiany AN, Waisman A, Kurschus FC. Imiquimod-induced psoriasis in mice depends on the IL-17 signaling of keratinocytes. J Invest Dermatol. 2019;139(5):1110–1117. doi: 10.1016/j.jid.2019.01.006</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Su Y, Huang J, Zhao X, et al. Interleukin-17 receptor D constitutes an alternative receptor for interleukin-17A important in psoriasis-like skin inflammation. Sci Immunol. 2019;4(36):eaau9657. doi: 10.1126/sciimmunol.aau9657</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Schmauch E, Severin Y, Xing X, et al. Targeting IL-1 controls refractory pityriasis rubra pilaris. Sci Adv. 2024;10(27):eado2365. doi: 10.1126/sciadv.ado2365 EDN: TIYKPY</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Fuchs-Telem D, Sarig O, van Steensel MA, et al. Familial pityriasis rubra pilaris is caused by mutations in CARD14. Am J Hum Genet. 2012;91(1):163–170. doi: 10.1016/j.ajhg.2012.05.010</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Vanderhooft SL, Francis JS, Holbrook KA, et al. Familial pityriasis rubra pilaris. Arch Dermatol. 1995;131(4):448–453. doi: 10.1001/archderm.1995.01690160076012 EDN: XYQTPK</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Vasher M, Smithberger E, Lien MH, Fenske NA. Familial pityriasis rubra pilaris: report of a family and therapeutic response to etanercept. J Drugs Dermatol. 2010;9(7):844–850.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Wang D, Chong VC, Chong WS, Oon HH. A review on pityriasis rubra pilaris. Am J Clin Dermatol. 2018;19(3):377–390. doi: 10.1007/s40257-017-0338-1 EDN: OVFWBQ</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Spoerri I, Herms S, Eytan O, et al. Immune-regulatory genes as possible modifiers of familial pityriasis rubra pilaris―lessons from a family with PRP and psoriasis. J Eur Acad Dermatol Venereol. 2018;32(10):e389–e392. doi: 10.1111/jdv.15029</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Akiyama M, Sugiyama-Nakagiri Y, Sakai K, et al. Mutations in lipid transporter ABCA12 in harlequin ichthyosis and functional recovery by corrective gene transfer. J Clin Invest. 2005;115(7):1777–1784. doi: 10.1172/JCI24834</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Takeichi T, Hamada T, Yamamoto M, et al. Patients with keratinization disorders due to ABCA12 variants showing pityriasis rubra pilaris phenotypes. J Dermatol. 2024;51(1):101–105. doi: 10.1111/1346-8138.16967 EDN: PPGTRL</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Shi P, Chen W, Lyu X, et al. Loss-of-function mutations in Keratin 32 gene disrupt skin immune homeostasis in pityriasis rubra pilaris. Nat Commun. 2024;15(1):6259. doi: 10.1038/s41467-024-50481-z EDN: HEDMJR</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Kawara S, Miyake M, Oiso N, Kawada A. Pityriasis rubra pilaris with preceding cytomegalovirus infection. Dermatology. 2009;219(4):350–352. doi: 10.1159/000240018</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Orta Z, Çağatay AA. HIV-associated pityriasis rubra pilaris type 6: first case report from Türkiye. Infect Dis Clin Microbiol. 2025;7(3):323–325. doi: 10.36519/idcm.2025.550 EDN: OHYXPD</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Zhou T, Al Muqrin A, Abu-Hilal M. Updates on pityriasis rubra pilaris: a scoping review. J Cutan Med Surg. 2024;28(2):158–166. doi: 10.1177/12034754231223159 EDN: GNCUPJ</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Mufti A, Lytvyn Y, Maliyar K, et al. Drugs associated with development of pityriasis rubra pilaris: a systematic review. J Am Acad Dermatol. 2021;84(4):1071–1081. doi: 10.1016/j.jaad.2020.07.052 EDN: WGZOZB</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Davis AE, Raine BE, Swartzman I, et al. Rethinking pityriasis rubra pilaris as a paraneoplastic syndrome: two cases of pityriasis rubra pilaris with concomitant underlying malignancy. JAAD Case Rep. 2023;32:90–95. doi: 10.1016/j.jdcr.2022.12.007 EDN: XMKUKY</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Gasslitter I, Ragg JL, Schmidt E, et al. Coincidence of bullous pemphigoid and pityriasis rubra pilaris. Acta Derm Venereol. 2022;102:adv00674. doi: 10.2340/actadv.v102.1289 EDN: NUNAWI</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Genovese G, Muratori S, Berti E, Marzano AV. Bullous erythroderma: novel association of pityriasis rubra pilaris with bullous pemphigoid. Clin Exp Dermatol. 2019;44(1):73–75. doi: 10.1111/ced.13718</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>César A, Cruz M, Mota A, Azevedo F. Erythroderma. A clinical and etiological study of 103 patients. J Dermatol Case Rep. 2016;10(1):1–9. doi: 10.3315/jdcr.2016.1222</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Adaskevich VP. Diagnostic indexes in dermatology. Moscow: Meditsinskaya kniga; 2004. P. 137–139. (In Russ.) EDN: EAIBJH</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Griffiths CE, Barker J, Bleiker TO, et al., editors. Rook’s textbook of dermatology. Chapter 23: Erythroderma. 9th ed. Wiley-Blackwell; 2016. P. 23.1–23.15. ISBN: 978-1118441183</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Boyd AS, Menter A. Erythrodermic psoriasis. Precipitating factors, course, and prognosis in 50 patients. J Am Acad Dermatol. 1989;21(5 Pt 1):985–991.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Singur LG, Shatskaya MV, Singur OA, et al. Erythrodermia as a polyethyological pathology of the skin: clinical and morphological aspects. Zdorov’e. Meditsinskaya ehkologiya. Nauka. 2019;(2):30–44. doi: 10.5281/zenodo.3262058 EDN: TOWZZY</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Ogawa K, Okada Y. The current landscape of psoriasis genetics in 2020. J Dermatol Sci. 2020;99(1):2–8. doi: 10.1016/j.jdermsci.2020.05.008 EDN: WCDFRW</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Frare CP, Blumstein AJ, Paller AS, et al. CARD14-associated papulosquamous eruption (CAPE) in pediatric patients: three additional cases and review of the literature. Pediatr Dermatol. 2021;38(5):1237–1242. doi: 10.1111/pde.14779 EDN: FRGASH</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Moritz RK, Huynh J, Poch G, et al. Is Kaposi sarcoma a novel comorbidity of cutaneous lymphoma? A systematic review of the literature. J Dtsch Dermatol Ges J Ger Soc Dermatol. 2025;23(4):467–477. doi: 10.1111/ddg.15625 EDN: ZGGHJJ</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Miyashiro D, Sanches JA. Erythroderma: a prospective study of 309 patients followed for 12 years in a tertiary center. Sci Rep. 2020;10(1):9774. doi: 10.1038/s41598-020-66040-7 EDN: ULNGDJ</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Harvey NT, Chan J, Wood BA. Skin biopsy in the diagnosis of inflammatory skin disease. Aust Fam Physician. 2017;46(5):283–288.</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Zhukov A, Belousova I, Khairutdinov V, et al. Level of the proliferative activity of lymphocytes in case of mycosis fungoides and plaque parapsoriasis. Vestnik dermatologii i venerologii. 2014;(1):30–36. EDN: RYBRSH</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Jankowska-Konsur A, Kobierzycki C, Grzegrzółka J, et al. Podoplanin expression correlates with disease progression in mycosis fungoides. Acta Derm Venereol. 2017;97(2):235–241. doi: 10.2340/00015555-2517</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Egner JR. Abeloff’s clinical oncology. JAMA. 2010;303(11):1097. doi: 10.1001/jama.2010.288</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Seremet T, Di Domizio J, Girardin A, et al. Immune modules to guide diagnosis and personalized treatment of inflammatory skin diseases. Nat Commun. 2024;15(1):10688. doi: 10.1038/s41467-024-54559-6 EDN: DBGBAB</mixed-citation></ref></ref-list></back></article>
